Stem Cell Therapy for Arthritis

Experts are researching ways to use stem cells to treat arthritis in the knee and other joints. Many doctors already use stem cell therapy to treat arthritis, but it is not considered standard practice. Stem cell therapy is one of several non-surgical treatments for arthritis pain

Read more
Innovative Life-Saving Therapy with Remarkable Healing Properties Could Fulfill Urgent Medical Need in COVID-19 Treatment – HospiMedica

Image: ExoFlo (Photo courtesy of Direct Biologics, LLC) Direct Biologics, LLC (Austin, TX, USA) has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a Phase I/II clinical trial using its extracellular vesicle (EV) product ExoFlo in the treatment of Acute Respiratory Distress Syndrome (ARDS). This trial represents its first non-COVID-19-related investigational approval. Direct Biologics is the only EV company with INDs approved for the full breadth of COVID-19 indications, as well as ARDS

Read more
Mesenchymal Stem Cells Market To Observe Exponential Growth In Near Future : Cell Applications Inc. Cyagen Biosciences Inc. Axol Bioscience Ltd….

Polaris Market Research released the latest research report on the Mesenchymal Stem CellsMarket. The report provides a detailed assessment of the market by highlighting different aspects of information, including market size, share, CAGR value, driving factors, restrictions, opportunities and threats. This information can help stakeholders make appropriate decisions before investing

Read more
Innovative Life-Saving Therapy with Remarkable Healing Properties Could Fulfill Urgent Medical Need in COVID-19 Treatment – Daily clinical news -…

By HospiMedica International staff writersPosted on 23 Jul 2021 Direct Biologics, LLC (Austin, TX, USA) has received approval from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a Phase I/II clinical trial using its extracellular vesicle (EV) product ExoFlo in the treatment of Acute Respiratory Distress Syndrome (ARDS). This trial represents its first non-COVID-19-related investigational approval. Direct Biologics is the only EV company with INDs approved for the full breadth of COVID-19 indications, as well as ARDS.

Read more
ExoFlo From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment – PRNewswire

Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) AUSTIN, Texas, July 20, 2021 /PRNewswire/ -- As intensive care units across the country fill to capacity, hospital beds are in dangerously short supply, and deaths from COVID-19 continue to spike, doctors from medical centers coast to coast are reporting on the remarkable healing properties of ExoFlo, an innovative life-saving therapy that leverages the anti-inflammatory and regenerative effects of bone-marrow derived mesenchymal stem cells, when used on their most seriously ill COVID-19 patients. The physicians note that utilizing ExoFlo, administered as a single IV infusion, is safe and efficacious and is saving lives on a consistent basis. One of the product's earliest advocates, Dr.

Read more
Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome -…

AUSTIN, Texas, July 14, 2021 /PRNewswire/ --Direct Biologics, a market-leading innovator and cGMP manufacturer of regenerative biologic products, announced today that the U.S Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to conduct a Phase I/II clinical trial using ExoFlo in the treatment ofAcute Respiratory Distress Syndrome (ARDS). The Company now has four IND protocols approved by the FDA. This trial represents its first non-COVID-19-related investigational approval.

Read more